Table 4 Univariate and multivariate analysis for overall survival

Late-irAEs (any grade)

Yes vs No

0.28 (0.13–0.62); p = 0.0015

0.25 (0.11–0.55); p = 0.0006

Primary tumor (NSCLC vs)

 Melanoma

0.43 (0.20–0.95); p = 0.0363

0.39 (0.18–0.86); p = 0.0207

 Kidney

0.62 (0.19–2.05); p = 0.4366

0.39 (0.12–1.33); p = 0.1340

 Others

1.01 (0.13–7.48); p = 0.9897

0.65 (0.08–4.88); p = 0.6811

Sex

Male vs Female

0.94 (0.18–3.07); p = 0.6837

–

Age (continuous)

1.02 (0.98–1.05); p = 0.2110

–

Treatment line

Non-first vs first

2.11 (0.94–4.82); p = 0.0688

–

ECOG PS

≥ 2 vs 0–1

0.74 (0.18–3.07); p = 0.6837

–

N of metastatic sites

≥ 3 vs < 3

1.05 (0.56–1.95); p = 0.8631

–